Biotech IPO window stays open as issuance nears record
- Offerings continue despite wider new-issue weakness
- Record convertibles lift total issuance toward 2020 peak
- Prepared, clinically differentiated candidates favored for 2027
Biotech IPOs could extend into December as company-specific catalysts sustain issuance compared to broader weaknesses in the listings market, according to industry participants.
Offerings from biotech issuers have remained on the calendar despite a steep sell-off in technology stocks and recent IPOs, said Matthew Kennedy, a markets strategist at Renaissance Capital. The wider decline has not completely shut the IPO calendar, creating scope for further activity before year-end, he said.
The biotech industry has remained a relative bright spot during an otherwise challenging period for IPOs, one ECM banker said. The sector has been partly insulated from broader equity market movements because performance is driven more by company-specific developments, the banker added.
North American biomed equity and equity-linked issuance has reached USD 70.54bn across 435 transactions in 2026, its second-highest annual volume since at least 2004, according to Dealogic data as of 11 November. Proceeds have increased 76% from USD 40bn in 2025, even as the deal count declined from 448. Average proceeds per transaction have risen to approximately USD 162m from USD 89m last year.
IPO volume has nearly quadrupled to USD 10bn from USD 2.55bn, making 2026 the third-strongest year since 2004, behind only 2020 and 2021. Follow-on issuance has increased 35% to USD 40.27bn. Convertible issuance has reached a record USD 20.28bn, almost three times the USD 7.52bn raised in 2025 and well above the previous high of USD 12.05bn in 2006.
The lively activity has been concentrated in larger financings. Deals worth at least USD 200m accounted for approximately three-quarters of proceeds while representing around one-quarter of completed transactions. Six financings worth at least USD 1bn generated approximately USD 10.48bn. The largest deals included USD 3bn and USD 2bn convertible offerings from Moderna and Summit Therapeutics, respectively. Revolution Medicines completed a USD 1.73bn follow-on.
Access still selective
The sector has performed well partly because an IPO can still serve primarily as a financing event rather than an exit for existing shareholders, said Louis Lehot, a partner at Foley & Lardner.
Many drug developers list before generating commercial revenue, leaving investors accustomed to assessing scientific, clinical, regulatory, and intellectual-property risks, he said. Investors focus particularly on whether the financing provides sufficient runway to reach the next potentially value-changing milestone.
“Today’s market is not really ‘open’ or ‘closed.’ It is open for the right companies,” Lehot said.
Issuers with compelling clinical evidence, credible crossover backing, sufficient scale, and clear uses for their proceeds should continue to reach the market, he said. Earlier-stage or less differentiated businesses are more likely to rely on private rounds, private investments in public equity, and other alternatives, Lehot added.
The industry has also provided investors with diversification from technology, said Daniel Klausner, a managing director at Houlihan Lokey.
“When I look at the pipeline, biotech has had a pretty good year in terms of returns, of course, to some degree because it is a bit of a counterweight to tech,” Klausner said.
The SPDR S&P Biotech ETF has returned 26% year to date, compared with 11.2% for the S&P 500 total-return index.
The public pipeline has also expanded. Thirty-two biomed companies have publicly filed for US IPOs this year, compared with 14 in 2025 and 25 in 2024, according to Dealogic.
Twenty-five of this year’s filers have priced, with a median period of approximately 20 days between filing and pricing. Nine candidates have filed since 1 September, of which eight subsequently completed offerings totaling approximately USD 1.76bn.
The post-Labor Day cohort included Lycia Therapeutics’ USD 318m October IPO, City Therapeutics’ USD 200m offering, Bambusa Therapeutics’ USD 169m deal, and Iambic Therapeutics’ USD 150m listing. Aspen Neuroscience raised a further USD 141m later in October.
All seven US biotech listings completed in October priced within their initial ranges, according to S&P Global Market Intelligence. Performance subsequently diverged, with Lycia rising 67% on its debut and remaining approximately 74% above its offer price as of 12 November, while Iambic and Aspen were trading approximately 8% and 15% below issue, respectively.
Many current candidates had been preparing to list for one or two years, said Remo Moomiaie-Qajar, CEO of Axiom Biosciences.
“These are companies that were geared up to list probably a year, maybe even two years ago,” he said.
Pipeline into 2027
More biotech offerings are likely before year-end, but the increase should not be characterized as a flood, Lehot said. The pipeline for the first half of 2027 looks constructive but remains selective, he said.
The strongest candidates are likely to use late-2026 financings to extend their cash runways and generate additional clinical evidence before approaching public investors, according to Lehot.
Issuers with sufficient capital can retain the option to pursue another private round, a strategic collaboration, an IPO or an acquisition, Lehot added.
Obesity and cardiometabolic disease, oncology, autoimmune and inflammatory diseases, RNA and genetic medicines, and ophthalmology are among the areas to watch. However, differentiated science, defensible intellectual property, and clinical evidence will matter more than the therapeutic category, he noted.
“Companies that wait for a perfect window before doing the work are usually too late when the window arrives,” Lehot said.
Drug developers now have a broader range of IPO, M&A and private-financing options than several years ago, Moomiaie-Qajar said. Reduced regulatory uncertainty over the past 12 to 18 months has also contributed to the improvement in financing and deal activity, he added.